BCR-ABL1 Kinase Domain Mutation Analysis in UAE | 1500 AED | 2026 DHA Guidelines

تحليل طفرة نطاق الكايناز BCR-ABL1 في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

ملخص تنفيذي: فحص الطفرة الجينية بدقة 99.9% لتقييم مقاومة الأدوية الموجهة في ابيضاض الدم النقوي المزمن.

✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing.
✔ Premium Logistics: Paid Hospital-Grade Home Collection with ISO Certified Cold-Chain Transport (VIP Mobile Phlebotomy).
✔ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation — connect with our clinical team.
✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview

BCR-ABL1 Kinase Domain Mutation Analysis detects specific point mutations within the kinase domain of the BCR-ABL1 fusion gene, pinpointing resistance to first‑line tyrosine kinase inhibitors (TKIs) such as imatinib. يوفر اختبار الطفرة في نطاق الكيناز BCR-ABL1 تحليلاً دقيقاً لمقاومة الأدوية الموجهة، مما يمكّن الأطباء من اختيار الجيل التالي من المثبطات المناسبة.

Feature	Our Test (BCR-ABL1 Kinase Domain Mutation Analysis)	Closest Alternative (BCR-ABL1 Quantitative RT‑PCR)
Precision / Method	Gold‑standard Sanger Sequencing for mutation identification	Real‑Time PCR measures transcript levels, not mutations
Clinical Utility	Detects resistance-conferring mutations (e.g., T315I) to guide TKI switch	Monitors minimal residual disease but cannot explain resistance mechanism
Speed / TAT	7–8 days	3–5 days

Physician Insight & Safety Protocol

“This analysis is a cornerstone in personalizing treatment for CML patients. As an expert in oncology, I emphasize that mutation detection guides the choice of next‑generation tyrosine kinase inhibitors, but always correlate results with clinical and hematological parameters. Any modification to therapy must be discussed with your treating physician.”

— Dr. PRABHAKAR REDDY, DHA License: 61713011

⚠️ Medication Warning: Do not discontinue prescribed medication without consulting your doctor.

Patient Safety Exclusion Criteria & Emergency Red Flags

Exclusion: Uncontrolled bleeding disorders, active infection at the collection site, recent anticoagulant therapy without physician clearance, or inability to provide informed consent.
Exclusion: Bone marrow collection requires evaluation of coagulation profile and platelet count; discuss with your physician if you are on blood thinners.
ER Red Flags: If you experience severe dizziness, chest pain, difficulty breathing, or prolonged bleeding after sample collection, seek emergency medical attention immediately.
Safety Note: All home collections are performed by DHA‑licensed phlebotomists under strict aseptic protocols; do not delay reporting any unusual symptoms.

Pre‑Test Information

A valid doctor’s prescription is required to proceed with this test, except for patients undergoing surgery, pregnancy monitoring, or pre‑travel medical clearance as per DHA guidelines. Bone marrow aspirate or peripheral blood sample must be transported immediately. Fasting is not required unless otherwise instructed.

Patient FAQ & Clinical Guidance

What is BCR-ABL1 kinase domain mutation analysis?

Direct Answer: BCR-ABL1 kinase domain mutation analysis detects mutations in the BCR-ABL1 gene that cause resistance to tyrosine kinase inhibitors like imatinib.

تحليل طفرة نطاق الكيناز BCR-ABL1 هو فحص جيني يكتشف الطفرات في جين BCR-ABL1 التي تسبب مقاومة لمثبطات التيروزين كيناز مثل إيماتينيب.

Why is this test needed?

Direct Answer: This is essential for CML patients experiencing suboptimal response or resistance to imatinib, as it detects actionable mutations guiding therapy change.

يحتاج المريض هذا الفحص عند فقدان الاستجابة للعلاج بمثبطات التيروزين كيناز، لتحديد الطفرات المسببة للمقاومة وتوجيه التغيير العلاجي.

How is the sample collected?

Direct Answer: A painless peripheral blood draw or a bone marrow aspirate is performed by a DHA‑licensed phlebotomist; our home collection service is available from 8 AM to 11 PM daily.

يتم جمع العينة عن طريق سحب دم وريدي بسيط أو رشافة نخاع العظم بواسطة فني مختص مرخص من هيئة الصحة بدبي، وتتوفر خدمة السحب المنزلي من 8 صباحاً حتى 11 مساءً يومياً.

Regulatory Compliance & Accreditation

Compliant with Federal Decree‑Law No. 41 of 2024 (Art. 87) and UAE PDPL (Patient Data Privacy).
For minors, mandatory parental consent is obtained in accordance with CDS Law 2026.
ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) — ensuring quality management and patient safety.
Facility License: 9834453.
Direct Billing & Insurance Support via WhatsApp: +971 54 548 8731.

دعم ثنائي اللغة متاح